Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedActivity from announced rounds
Develops neuro-metabolic therapeutics for schizophrenia and ALS
Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease